



Sheet 1 of 2

Form 1449* <b>INFORMATION DISCLOSURE STATEMENT</b> BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.: 740.013US2	Serial No. 08/955,572
	Applicant: Byoung S. Kwon	
	Filing Date: October 22, 1997	Group: 1647

**U. S. PATENT DOCUMENTS**

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
--------------------	-----------------	------	------	-------	----------	----------------------------

**FOREIGN PATENT DOCUMENTS**

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes   No
<i>BL</i>	99/36093	07/22/1999	PCT			

**OTHER DOCUMENTS**

(Including Author, Title, Date, Pertinent Pages, Etc.)

<i>BL</i>	Alderson, M.R., et al., "Molecular and Biological Characterization of Human 4-1BB and its Ligand ", <u>Eur. J. Immunol.</u> , 24, pp. 2219-2227, (1994)
	Armitage, R.J., "Identification of a source of biologically active CD40 ligand", <u>Eur. J. Immunol.</u> , Vol. 22, 2071-2076, (1992)
	Ellenhorn, J.D., et al., "In Vivo Administration of Anti-CD3 Prevents Malignant Progressor Tumor Growth", <u>Science</u> , Vol. 242, 569-571, (October 28, 1988)
	Leach, D.R., et al., "Enhancement of antitumor Immunity by CTLA-4 Blockade", <u>Science</u> , Vol. 271, 1734-1736, (March 22, 1996).
	Linsley, P.S., "Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule", <u>Science</u> , Vol 257, 792-795, (August 7, 1992)
	Melero, I., et al., "Monoclonal Antibodies Against the 4-1BB T-cell Activation Molecule Eradicate Established Tumors", <u>Nature Medicine</u> , 3 (6), pp. 682-685, (June 1997)
	Pollok, K., et al., "4-1BB T-Cell Antigen Binds to Mature B Cells and Macrophages, and Costimulates Pre-activated Splenic B Cells", <u>J. Immunol.</u> , Vol. 150, 275A, (May 1993)
	Pollok, K.E., et al., "Inducible T Cell Antigen 4-1BB", <u>J. Immunol.</u> , 150 (3), pp. 771-781, (1993)
	Schwarz, H., et al., "A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family", <u>Gene</u> , 134, 295-298, (1993)
<i>✓</i>	Sica, G., et al., "Modulation of the Immune Response Through 4-1BB", <u>Cancer Gene Therapy: Past Achievements and Future Challenges</u> , 355-362, (2000)

Examiner <i>Barbier</i>	Date Considered <i>1-10-02</i>
-------------------------	--------------------------------

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

12



Form 1449*	Atty. Docket No.: 740.013US2	Serial No. 08/955,572
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Byoung S. Kwon	
	Filing Date: October 22, 1997	Group: 1647

**OTHER DOCUMENTS**

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner  
Initial

ML	Strome, S.E., et al., "Enhanced Therapeutic Potential of Adoptive Immunotherapy by In Vitro CD28/4-1BB Costimulation of Tumor-Reactive T Cells Against a Poorly Immunogenic, Major Histocompatibility Complex Class I-Negative A9P Melanoma", <u>Journal of Immunotherapy</u> 23, 430-437, (2000)
T	Townsend, S.E., et al., "Tumor Rejection After Direct Costimulation of CD*+ T Cells by B7-Transfected Melanoma Cells", <u>Science</u> , Vol. 259, 368-370, (January 15, 1993)
V	Zhou, et al., "Characterization of Human Homologue of 4-1BB and its Ligand", <u>Immunol. Lett.</u> , 45, 67-73, (1995)

Examiner	Date Considered
----------	-----------------

\*Substitute Disclosure Statement Form (PTO-1449)

1-10-02

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.